PARP inhibitors coming of age

被引：21
|
作者：
Paluch-Shimon, Shani [1 ]
Cardoso, Fatima [2 ]
机构：
[1] Hadassah Univ Hosp, Sharett Inst Oncol, Jerusalem, Israel
[2] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2021年 / 18卷 / 02期
关键词：
BREAST-CANCER; BRCA; OLAPARIB;
D O I：
10.1038/s41571-020-00452-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The much anticipated results from two phase III studies evaluating the clinical efficacy of poly(ADP-ribose) polymerase (PARP) inhibition in patients with advanced-stage breast cancer harbouring a germline mutation in BRCA1/2 have established new therapeutic opportunities and yet, have left us with several ongoing questions.
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [1] A coming of age for immune checkpoint inhibitors in cancer
    Nipp, Ryan D.
    Gainor, Justin F.
    IMMUNOTHERAPY, 2019, 11 (08) : 647 - 650
  • [2] PARP inhibitors and more
    Bose, Chinmoy K.
    Basu, Nirban
    JOURNAL OF THE TURKISH-GERMAN GYNECOLOGICAL ASSOCIATION, 2015, 16 (02) : 107 - 110
  • [3] PARP inhibitors for the treatment and prevention of breast cancer
    Vinayak S.
    Ford J.M.
    Current Breast Cancer Reports, 2010, 2 (4) : 190 - 197
  • [4] PARP inhibitors are not all equal
    Dent, Paul
    CANCER BIOLOGY & THERAPY, 2013, 14 (10) : 873 - 874
  • [5] PARP inhibitors in breast cancer: Current clinical development and perspectives
    Robbe, Julie
    Moretta, Jessica
    Vicier, Cecile
    Sabatier, Renaud
    Nogues, Catherine
    Goncalves, Anthony
    BULLETIN DU CANCER, 2020, 107 (10) : 1024 - 1041
  • [6] Development of PARP inhibitors in gynecological malignancies
    Ang, Yvonne L. E.
    Tan, David S. P.
    CURRENT PROBLEMS IN CANCER, 2017, 41 (04) : 273 - 286
  • [7] PARP Inhibitors Resistance: Mechanisms and Perspectives
    Giudice, Elena
    Gentile, Marica
    Salutari, Vanda
    Ricci, Caterina
    Musacchio, Lucia
    Carbone, Maria Vittoria
    Ghizzoni, Viola
    Camarda, Floriana
    Tronconi, Francesca
    Nero, Camilla
    Ciccarone, Francesca
    Scambia, Giovanni
    Lorusso, Domenica
    CANCERS, 2022, 14 (06)
  • [8] A review on mechanisms of resistance to PARP inhibitors
    Desai, Chirag
    Pathak, Anand
    Limaye, Sewanti
    Maniar, Vashishth
    Joshi, Archita
    INDIAN JOURNAL OF CANCER, 2022, 59 : S119 - S129
  • [9] The Landscape of PARP Inhibitors in Solid Cancers
    Muzzana, Marta
    Broggini, Massimo
    Damia, Giovanna
    ONCOTARGETS AND THERAPY, 2025, 18 : 297 - 317
  • [10] PARP inhibitors in metastatic prostate cancer
    Taylor, Amy K.
    Kosoff, David
    Emamekhoo, Hamid
    Lang, Joshua M.
    Kyriakopoulos, Christos E.
    FRONTIERS IN ONCOLOGY, 2023, 13
12345